Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-726-8 | CAS number: 109-99-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
The metabolism, disposition and toxicokientics of tetrahydrofuran have been well characterized. Tetrahydrofuran was administered to rats and mice in oral gavage metabolism and disposition studies. It has also been measured in the blood of various test animal species after inhalation exposures. The in vitro metabolism of tetrahydrofuran was determined using liver microsomes from rats, mice and humans. Also, dermal absorption rates were determined following administration of tetrahydrofuran to human cadaver skin samples. In a non-guideline study that was well-conducted and documented and was GLP-compliant, male and female Fischer 344 rats and B6C3F1 mice were dosed by single gavage dose with 14C-tetrahydrofuran at dose levels of 50 and 500 mg/kg. Total radioactivity was quantitated in expired air, plasma, urine and feces at various time points up to 168 hours post-dosing. In rats, tetrahydrofuran was rapidly absorbed and metabolized with the majority of radioactivity eliminated as CO2 in both sexes of rat (20.3% of dose, 500 mg/kg bwt; 47.6% of dose, 50 mg/kg bwt). Based on plasma samples for low dose male and female rats, a Tmax of approximately 4 hours was obtained for both sexes. The Tmax value for male rats in the high dose group was 8 hours, about twice that of the low dose. Female rats at the high dose level had an average Tmax value of 3.2 hours but individual female rat values varied widely. The average Cmax values for high dose male and female rats were within one standard deviation of each other. The Cmax values for the 50 mg/kg bwt dose level rats were approximately 4-fold lower than for the high dose group. The half-life for total radioactivity in the 500 mg/kg bwt dose rats was 53.5 +/-6.6 hours, comparable to the half-life value for the low dose rats of 51.3 +/- 2.8 hours. Rats were sacrificed at 168 hours and tissue samples collected, oxidized and analyzed for radioactivity by liquid scintillation counting. At both dose levels and in both male and female rats, the average of all tissues combined represented an average of 6.8% of the dose. The carcasses contained the most radioactivity, followed by muscle, liver and skin.
As in the case of rats, tetrahydrofuran was rapidly absorbed and metabolized with the majority of radioactivity eliminated as CO2 in both sexes of mice following oral gavage administration (43.6% of dose, 500 mg/kg bwt; 71.6% of dose, 50 mg/kg bwt). Pharmacokinetic parameters were calculated based on radioactivity analysis of plasma samples from mice. The 500 mg/kg bwt male and female mouse plasma samples each had similar Tmax values (males, 0.8 +/- 0.3 hours; females, 1.0 +/- 0.0 hours). These values were approximately twice that of the 50 mg/kg bwt mice (males, 0.5 +/- 0.0 hours; females, 0.4 +/- 0.1 hours). The half-life for the 500 mg/kg bwt male mice was within one standard deviation of the 50 mg/kg bwt value for male and female mice (54.1 +/- 12.2 hours). The female high dose mice had a wide variation in half-life values (98.5 +/- 41.0 hours). Mice were sacrificed serially from 15 minutes to 168 hours and tissue samples collected, oxidized and analyzed for radioactivity for the high and low dose male mice. Most tissue concentrations were at a maximum at the 2-hour sacrifice for the high dose, and 30 minutes for the low dose. For all time points, radioactivity was highest in the carcass, liver, kidney, muscle, and gastrointestinal tract.
Liver microsomes from rats, mice and humans were incubated with 70 micromolar tetrahydrofuran for up to 55 minutes. There were no significant differences in the in vitro half-life values between male and female rats or mice. The order of decreasing half-lives (min) were 40.1 (rat), 28.6 (human) and 9.0 (mouse), respectively. There was no difference observed in calculated CLint values between males and females in either rats or mice. The CLint was greatest for mice and decreased for the other species as follows: mouse > rat > human. These values were calculated by two different methods that gave comparable results (160.5, 30.6 and 27.31 mL/min/kg, respectively, versus 205.4, 30.6, and 28.6 mL/min/kg). Comparison of hepatic blood flow relative to CLint values indicates that it is likely the mouse liver can metabolize all tetrahydrofuran present in the blood during first pass. The similarity in value of hepatic blood flow and CLint in humans suggests that tetrahydrofuran will also be extensively metabolized during first pass. A single metabolite was identified in all species as gamma hydroxybutyric acid, which, can be metabolized through the tricarboxylic acid (TCA) cycle to yield carbon dioxide.
A physiologically-based, pharmacokinetic (PBPK) model has been developed to predict levels of human exposure under various exposure scenarios. Model agreement was found to be satisfactory when compared with field data (worker exposures) from 3 of 4 reported studies. The PBPK model was applied to predict biological levels of exposure to tetrahydrofuran following repeated occupational exposures. It was proposed that the PBPK model results were reliable in predicting biological levels of tetrahydrofuran occupational exposure and that the model might serve as the basis for establishment of a biological exposure index (BEI).
In a well-conducted and documented guideline study, the in vitro absorption of tetrahydrofuran through human cadaver skin was measured in static diffusion cells after application of either neat (100%) tetrahydrofuran or as 10% or 30% aqueous solutions. In separate experiments, dermal absorption was measured for either 10- or 60-minute periods or for a 14-hour period. The 10%- and 30%-tetrahydrofuran aqueous solutions did not significantly alter the barrier function of the skin, as assessed by the percutaneous absorption of 3H20. However, neat (100%) tetrahydrofuran exposure to the skin did alter the skin’s barrier function, suggesting damage to the stratum corneum. Therefore, the results from the 10%- and 30%-tetrahydrofuran solutions may better represent human skin permeability in un-damaged skin from short-term exposures. Two permeability coefficients (Kp) were calculated to be 0.015 ± 0.003 cm/hr, for the absorption period of t = 1-6 hrs, and 0.011 ± 0.002 cm/hr, for the absorption period of t = 4-14 hrs, based on the mean rate of penetration derived from the time spans indicated as observed during the 14 hour dose duration study. The first of these may represent the upper limit of initial or early steady state like penetration whereas the second may represent a more conservative value for tetrahydrofuran absorption over longer periods of time. Based on the results obtained in these studies, tetrahydrofuran may be considered a fast penetrant of human skin.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.